Department of Pediatrics Click here for the Department of Pediatrics Home Page Click here for the UC Irvine Home Page Click here for the School of Medicine Home Page
 
 
 
 

Division of Pediatric Endocrinology

When a family has concerns about a child’s growth and development, waiting for answers only prolongs the apprehension. Our clinical mission is to provide timely endocrine services to our patients, offering quality treatment and early intervention while minimizing delays.

Learn more about our clinical services ›

The Division of Pediatric Endocrinology also is dedicated to training future healthcare professionals to properly diagnose and treat children with a wide variety of conditions, including diabetes and disorders of the pituitary, thyroid, parathyroid and adrenal glands. Under an affiliation agreement with UC Irvine Health and the UC Irvine School of Medicine, our faculty members provide training and clinical services at Gottschalk Medical Plaza on the UC Irvine campus and at CHOC Children's Hospital of Orange County.

The division also is committed to advancing research into disorders of the endocrine system. Among the research studies underway are:

  • Type 1 Diabetes (T1D) TrialNet “Pathway to Prevention” — By identifying the relatives of people with T1D who are at risk of the disease, this study can help slow the progression of T1D in new-onset patients and delay or prevent the emergence of the disease in at-risk relatives.

  • Type 1 Diabetes Exchange — The Pediatric Diabetes Consortium (PDC), comprised of six centers including UC Irvine, continues to collect data on about 1,000 pediatric patients from the time of their T1D diagnosis. Participants are asked to join the T1D Exchange registry, making their data available as part of the national registry dataset, thus enhancing the data we have on the early course of T1D.

  • Growth Hormone Post-Marketing Surveillance Studies — the Norditropin® National Registry is a multi-center, open-label, post-marketing surveillance study available to all patients being treated with Norditropin® for growth failure associated with an inadequate secretion of growth hormone. The primary objective of these studies is to collect data on the long-term safety, growth and pharmo-dynamic response of Norditropin® as used in clinical practice in the United States.

Our Faculty

  • Ajanta Naidu, MD, FACE, MBA — director, UC Irvine Health Pediatric Endocrinology and Diabetes Services
  • Amrit Bhangoo, MD
  • Mario Brakin, MD
  • Christine Chou, MD
  • Susan Clark, MD
  • Mark W. Daniels, MD
  • Timothy K. Flannery, MD
  • Nikta Forghani, MD
  • Rebecca Hicks, MD
  • Christina Reh, MD
  • Lien N. Trinh, MD
spacer